In patients with type 2 diabetes (T2D), the use of GLP-1 receptor agonists was associated with a significantly lower risk for lung cancer than the use of DPP-4 inhibitors. GLP-1 receptor agonist use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback